<DOC>
	<DOCNO>NCT02272855</DOCNO>
	<brief_summary>The purpose study determine HF10 combination ipilimumab effective patient stage IIIB , IIIC , IV unresectable metastatic melanoma .</brief_summary>
	<brief_title>A Study Combination Treatment With HF10 Ipilimumab Patients With Unresectable Metastatic Melanoma</brief_title>
	<detailed_description>The study design assess efficacy safety repeat administration intratumoral injection HF10 1x10^7 TCID50/mL combination intravenous infusion 3mg/kg ipilimumab . This single arm , open label Phase II trial , evaluate efficacy , safety tolerability HF10 treatment combination administration immunologic checkpoint inhibitor , ipilimumab ( anti-CTLA-4 monoclonal antibody ) . The study population include patient Stage IIIB , IIIC IV unresectable metastatic malignant melanoma ipilimumab-eligible . Patients receive dose 1 x 10^7 TCID50/mL HF10 ( total 6 injection ; first 4 injection 1-week interval ; remain 2 injection 3-week interval ) + ipilimumab 3 mg/kg ipilimumab ( total 4 intravenous infusion , administer 3-week interval ) . Following combination therapy , patient may continue receive dose level HF10 ( 1 x 10^7 TCID50/mL ) alone additional 13 injection ( total 19 injection = 1 year ) tolerate study treatment , respond , stable disease , progressive disease clinically significant judgment Investigator .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must Stage IIIB , IIIC IV melanoma , unresectable/unresected histologically confirm diagnosis metastatic malignant melanoma . 2 . Patients must measurable nonvisceral lesion ( ) evaluable modify World Health Organization ( mWHO ) criterion immunerelated response criterion ( irRC ) . 3 . Patients must ≥ 18 year age . 4 . Patients must life expectancy ≥ 24 week . 5 . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 6 . Patients must adequate hepatic function , define Total bilirubin level ≤ 1.5 x upper limit normal [ ULN ] ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) AST/ALT level ≤ 2.5 x ULN , ≤ 5 x ULN liver metastases present . 7 . Patients must adequate renal function , define serum creatinine ≤ 1.5 x ULN creatinine clearance ( calculate ) ≥ 60 mL/min/1.73 m2 patient creatinine &gt; 1.5 x ULN . 8 . Patients must adequate bone marrow function , define Absolute neutrophil count ≥1,500/µL Platelet count ≥ 75,000/ µL 9 . Patients must know bleed diathesis coagulopathy would make intratumoral injection biopsy unsafe . 10 . Patients must ipilimumabeligible . ( This include : 1 ) patient previously untreated ipilimumab ; 2 ) patient previously treat ( 1 year previously ) ipilimumab use route administration intravenous infusion ; 3 ) patient previously treat antitumor agent intravenous ipilimumab ) . 11 . Men woman childbearing potential must agree use adequate contraception time consent 30 day final study treatment . 12 . Females childbearing potential must negative urine serum pregnancy test within one week prior start treatment . 13 . Patients must able understand willing sign write informed consent document . 1 . Patients receive chemotherapy radiotherapy within 4 week injection HF10 , history Grade 4 adverse event presence adverse event Grade 2 great , except alopecia , result anticancer agent administer 4 week prior HF10 injection . 2 . Patients receive antiherpes medication within 1 week prior initiate HF10 treatment . 3 . Patients history significant tumor bleeding , coagulation bleeding disorder . 4 . Patients target tumor could potentially invade major vascular structure ( e.g. , innominate artery , carotid artery ) , base unequivocal imaging finding . 5 . Patients Grade 2 great preexist neurologic abnormality ( CTCAE version 4.0 ) , include Grade 2 great peripheral neuropathy cause previous treatment . 6 . Patients clinically evident Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C virus ( HCV ) , EpsteinBarr virus ( EBV ) infection exclude . 7 . Medical history autoimmune disease ( e.g. , Crohn 's disease , ulcerative colitis ) diseases require systemic glucocorticoid immunosuppressive therapy . 8 . Patients previously treat ipilimumab administer intravenous infusion . 9 . Concurrent use investigational agent . 10 . Patients active CNS metastases carcinomatous meningitis , except patient CNS lesion treat evidence progression brain CT/MRI ≥ 3 month . 11 . Pregnant breastfeeding woman ; woman desire become pregnant within timeframe study also exclude . 12 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HF10</keyword>
	<keyword>HSV-1</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Phase II</keyword>
	<keyword>Stage IIIB melanoma</keyword>
	<keyword>Stage IIIC melanoma</keyword>
	<keyword>Stage IV melanoma</keyword>
	<keyword>Unresectable malignant melanoma</keyword>
	<keyword>Metastatic malignant melanoma</keyword>
	<keyword>Combination treatment</keyword>
	<keyword>Intratumoral injection</keyword>
</DOC>